Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | BCR | P11274 | 3/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428923 | 0.79 | KDR (0.55) | KDRABL1BCRADAADORA2A | |
| SCHEMBL12427767 | 0.78 | KDR (0.54) | KDRABL1BCRADAADORA2A | |
| SCHEMBL18641938 | 0.70 | KDR (0.88) | KDRABL1BCRADAADORA2A | |
| SCHEMBL23480585 | 0.68 | KDR (0.40) | KDRABL1BCRADAADORA2A | |
| SCHEMBL1741177 | 0.68 | KDR (1.00) | KDRABL1BCRADAADORA2A | |
| SCHEMBL1742909 | 0.68 | KDR (1.00) | KDRABL1BCRADAADORA2A | |
| SCHEMBL1741807 | 0.68 | KDR (1.00) | KDRABL1BCRADAADORA2A | |
| SCHEMBL1741143 | 0.68 | KDR (1.00) | KDRABL1BCRADAADORA2A | |
| SCHEMBL2075492 | 0.68 | KDR (0.69) | KDRABL1BCRADAADORA2A | |
| Hydrochloric Acid SCHEMBL1741360 | 0.67 | KDR (0.97) | KDRABL1BCRADAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | KDR 1449/4885ABL1 2258/4885BCR 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.